Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ) (R-PLQ)

Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.

Study Overview

• Status: Completed
• Conditions: Palliative Care; Hematological Malignancy; Platelet Transfusion
• Intervention / Treatment: Other: multi method questionary (developped by De Rosa, in 1995 and 2014)

• Study Type: Observational
• Enrollment (Actual): 45

Contacts and Locations

Study Locations

• France
  • Besançon, France, 25000
    • Moracchini

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient with advanced hematological malignancies, transfused in platelet regulary, hematologist's nurses who practice platelet transfusion and hematologist who prescribe the transfusion.

Description

Inclusion Criteria:

• major patient
• patient with advanced hematological malignancies
• patient transfused in platelet regularly (3 time at least in last month)
• medical practioner, hematologist, prescribing platelet transfusion at least one per week.
• nurse working in hematology, practicing platelet transfusion at lest one peer week.

Exclusion Criteria:

• minor patient
• non communicant patient
• non transfused platelet patient
• non voluntary patient or hematologist or nurses
• non graduated hematologist

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patient; patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient	Other: multi method questionary (developped by De Rosa, in 1995 and 2014); questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
hematologist; medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist	Other: multi method questionary (developped by De Rosa, in 1995 and 2014); questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
Nurses; nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse	Other: multi method questionary (developped by De Rosa, in 1995 and 2014); questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measure the impact of social representation on platelet transfusion practice	inner core and peripheral items of platelet transfusion of each participant will be collected until reaching saturation, it's to say that the repetition of some terms will be measured between each interview thank's to a questionnaire of at least two principals opened questions.	3 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Besançon

Publications and helpful links

General Publications

• McGrath P, Leahy M. Catastrophic bleeds during end-of-life care in haematology: controversies from Australian research. Support Care Cancer. 2009 May;17(5):527-37. doi: 10.1007/s00520-008-0506-1. Epub 2008 Sep 23.
• McGrath P, Holewa H. Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care (Engl). 2007 Mar;16(2):164-71. doi: 10.1111/j.1365-2354.2006.00745.x.
• Jeoffrion C, Dupont P, Tripodi D, Roland-Levy C. [Social representations of illness: Comparison of "expert" knowledge and "naive" knowledge]. Encephale. 2016 Jun;42(3):226-33. doi: 10.1016/j.encep.2015.12.007. Epub 2016 Jan 12. French.

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2019
• Primary Completion (Actual): June 1, 2019
• Study Completion (Actual): July 22, 2019

Study Registration Dates

• First Submitted: December 30, 2018
• First Submitted That Met QC Criteria: January 15, 2019
• First Posted (Actual): January 16, 2019

Study Record Updates

• Last Update Posted (Actual): July 25, 2019
• Last Update Submitted That Met QC Criteria: July 24, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: social representation
• Additional Relevant MeSH Terms: Neoplasms by Site; Hematologic Diseases; Neoplasms; Hematologic Neoplasms
• Other Study ID Numbers: P/2019/413

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: interview will be registered then transcribe on professional computer ans accessible only by the investigator and collaborators.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No